Pulse Biosciences (NASDAQ:PLSE) Trading Up 5.3% - Here's Why

Key Points

• Pulse Biosciences shares rose 5.3% to about $51.40 during Wednesday trading, although volume was 66% below the average session level.
• Analyst sentiment is generally positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus; the average price target is $45.25, below the current share price.
• The company reported weaker-than-expected quarterly results, including an adjusted loss of $0.36 per share versus the $0.29 estimate and revenue of $0.43 million versus $0.53 million expected.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s share price traded up 5.3% during trading on Wednesday . The company traded as high as $51.07 and last traded at $51.3950. 121,724 shares changed hands during trading, a decline of 66% from the average session volume of 362,152 shares. The stock had previously closed at $48.79.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PLSE. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer reaffirmed an "outperform" rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research report on Monday, August 10th. Wall Street Zen raised shares of Pulse Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday. Finally, Canaccord Genuity Group raised their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.25.

Pulse Biosciences Stock Up 15.9%

The company has a 50 day moving average price of $38.88 and a 200-day moving average price of $28.41. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -47.83 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.53 million. On average, analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Liane Teplitsky purchased 1,001 shares of the stock in a transaction on Tuesday, September 1st. The stock was purchased at an average price of $49.95 per share, for a total transaction of $49,999.95. Following the acquisition, the chief operating officer owned 4,095 shares in the company, valued at $204,545.25. This trade represents a 32.35% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 4,095 shares of company stock valued at $199,931 in the last quarter. Corporate insiders own 74.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its stake in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after buying an additional 680 shares during the period. Osterweis Capital Management Inc. acquired a new position in shares of Pulse Biosciences during the 2nd quarter valued at $28,000. Tower Research Capital LLC TRC raised its holdings in shares of Pulse Biosciences by 275.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. boosted its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock worth $70,000 after acquiring an additional 619 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in Pulse Biosciences in the 2nd quarter valued at $158,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.